NASDAQHealth CareBiotechnologySnapshot 2026-07-31
Reading NUVL? Create a free portfolio, then add this holding for ongoing Reports and tracking. Track it in a free portfolio. No credit card.
Create your account →Daily closes. Earnings/event dots are placed inline.
The reason to own it still holds.
View ThesisModerate volatility — typically moves about 1% a day.
View RiskNot enough reads yet
NUVL's growth in the healthcare sector needs to continue to justify its price. The company has steady recent performance, but it remains unprofitable. It trades at a low-confidence valuation, with no clear multiple to anchor. The market expects growth to match current prices, but risks remain. A 32% chance of missing next-quarter expectations could hurt the stock. Peer multiples imply a price about 12% above where it trades. This read is provisional.
Trailing returns as of 2026-07-16. NUVL is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 17 analysts currently covering NUVL (as of Jul 2026).
Based on 12 Wall Street analysts offering 12-month price targets for NUVL in the last 4 months.
A consensus fair price across 0 valuation methods, at three horizons. As of 2026-08-01. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Biotechnology — fair value, gap to price, and forward P/E.
Advances: Entry into Merger Agreement with GSK
Acquisition confirms growth strategy with GSK.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-07-16. EPS is implied from price ÷ P/E. Not investment advice.
Current $123.96
The last 12 months of price, then the range of analyst 12-month targets from today’s $123.96.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Advances: Entry into Merger Agreement with GSK
Acquisition aligns with growth in oncology.
Advances: Entry into Merger Agreement with GSK
GSK's investment boosts oncology strategy.
